On September 09, 2021 Tempest Therapeutics, Inc., a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, reported that management will present at the following investor conferences in September (Press release, Tempest Therapeutics, SEP 9, 2021, View Source [SID1234587496]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
H.C. Wainwright 23rd Annual Global Investment Conference available on-demand Monday, September 13, 2021 at 7:00 a.m. ET
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday September 22, 2021 at 9:55 a.m. ET
To access the live or archived recording of the company presentations, please visit the investor section of the Tempest website at View Source